Several factors have been shown to influence treatment outcomes in patients with HCV infection, including age, pretreatment HCV RNA levels, HCV genotype, alcohol consumption, liver fibrosis status, interleukin (IL)-28B variant's distribution, insulin resistance, and early virological kinetic changes during antiviral treatment. This evidence concerns the gene IFNL3 and Hepatic fibrosis.